Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma
- 28 February 2001
- journal article
- clinical trial
- Published by Elsevier in Respiratory Medicine
- Vol. 95 (2) , 136-146
- https://doi.org/10.1053/rmed.2000.1008
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthmaRespiratory Medicine, 2000
- Salmeterol/fluticasone propionate (50500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthmaRespiratory Medicine, 1999
- The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Assessing equivalence of inhaled drugsRespiratory Medicine, 1995
- Continuing Patient Care with Metered-Dose InhalersJournal of Aerosol Medicine, 1995
- Comparison of DiskusTMInhaler, a New Multidose Powder Inhaler, with DiskhalerTMInhaler for the Delivery of Salmeterol to Asthmatic PatientsJournal of Asthma, 1995
- CFCs and inhalersThe Lancet, 1994
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Regular inhaled beta-agonist treatment in bronchial asthmaThe Lancet, 1990